Q-omics provides the consensus-scored CYCSP35 profile across patient tissues and cancer cell-line models. CYCSP35 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYCSP35 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, CYCSP35 RNA expression shows 6,338 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUAD, and STAD as cancer lineages where CYCSP35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP35 survival associations across molecular data types. CYCSP35 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP35 RNA expression–survival associations across cancer types. High CYCSP35 expression shows unfavorable associations in KIRC, SKCM, LIHC, MESO and BLCA, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYCSP35 RNA expression.
This table summarizes CYCSP35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP35 shows higher tumor expression in LUAD. The LUAD box plot shows higher CYCSP35 RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p = .004).
This table shows molecular features associated with CYCSP35 in patient tissues and cancer cell lines. In patient samples, CYCSP35 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
